ACTIVLIM-Hemo: A new self-reported, unidimensional and linear measure of activity limitations in persons with haemophilia.

bleeding disorder, disability and health haemophilia, International Classification of Functioning (ICF), outcome assessment, questionnaire, rash analysis, scale

Journal

Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916

Informations de publication

Date de publication:
Jan 2023
Historique:
revised: 13 11 2022
received: 13 06 2022
accepted: 16 11 2022
pubmed: 13 12 2022
medline: 25 1 2023
entrez: 12 12 2022
Statut: ppublish

Résumé

To assess activity limitations in people with haemophilia (PwH), the self-reported Haemophilia Activity List (HAL) is widely employed, despite several methodological limitations impacting the interpretation of categorical scores. Modern psychometric approaches avoid these limitations by using a probabilistic model, such as the Rasch model. The ACTIVLIM is a Rasch-built measurement of activity limitations previously validated in several clinical conditions like neuromuscular disorders. This study sought to develop the ACTIVLIM-Hemo, meaning an ACTIVLIM scale version specifically adapted to assess daily activity limitations in adult PwH. Daily activities were assessed as "impossible," "difficult" or "easy" by 114 PwH (median age of 44 years) with 63 of them reassessed after 12 days. The Rasch Rating Scale model was used to identify activities delineating a unidimensional and linear scale unbiased by demographic and clinical status. Concurrent validity was determined through correlation with the HAL sub-scores and sum score. The ACTIVLIM-Hemo included 22 pertinent activities, with difficulties independent of demographic and clinical conditions, allowing a reliable measure of activity limitations (PSI = .92) expressed on a linear and unidimensional scale in PwH (7%-100 % range, ceiling effect of 1/114) with excellent test-retest reliability (ICC = .978). Spearman rank correlations between ACTIVLIM-Hemo and HAL sub-scores ranged between .623 and .869. The ACTIVLIM-Hemo is an easy-to-administer, valid and reliable alternative to HAL in assessing activity limitations in PwH. Its invariant scale can be used across conditions and time to compare the functional status of PwH over a wide measurement range.

Identifiants

pubmed: 36508315
doi: 10.1111/hae.14705
pmc: PMC10107861
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

317-328

Subventions

Organisme : Pfizer Inc.
ID : 55563735

Informations de copyright

© 2022 The Authors. Haemophilia published by John Wiley & Sons Ltd.

Références

Arthritis Rheum. 2007 Dec 15;57(8):1358-62
pubmed: 18050173
Occup Med (Lond). 2016 Aug;66(6):496-7
pubmed: 27067913
Stroke. 1998 Sep;29(9):1843-9
pubmed: 9731606
Haemophilia. 2023 Jan;29(1):317-328
pubmed: 36508315
Haemophilia. 2018 Nov;24(6):988-994
pubmed: 30295404
Stroke. 2012 Mar;43(3):815-23
pubmed: 22223234
Haemophilia. 2011 Mar;17(2):204-8
pubmed: 21332881
Am J Sports Med. 2001 Mar-Apr;29(2):213-8
pubmed: 11292048
J Orthop Sports Phys Ther. 2016 Mar;46(3):200-16
pubmed: 26813750
Am J Sports Med. 2001 Sep-Oct;29(5):600-13
pubmed: 11573919
Haemophilia. 2012 Jul;18 Suppl 4:125-30
pubmed: 22726095
Ann Rheum Dis. 2007 Aug;66(8):1098-105
pubmed: 17170054
Haemophilia. 2020 Aug;26 Suppl 6:1-158
pubmed: 32744769
Am J Ind Med. 1996 Jun;29(6):602-8
pubmed: 8773720
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
J Rheumatol. 1988 Dec;15(12):1833-40
pubmed: 3068365
Res Dev Disabil. 2017 Jan;60:285-294
pubmed: 28341237
Haemophilia. 2021 Nov;27(6):1062-1070
pubmed: 34498348
Arch Phys Med Rehabil. 1989 Apr;70(4):308-12
pubmed: 2535599
Haemophilia. 2006 Sep;12(5):518-25
pubmed: 16919083
J Hand Surg Eur Vol. 2021 Feb 8;:1753193421991485
pubmed: 33557681
Res Pract Thromb Haemost. 2019 Mar 12;3(2):184-192
pubmed: 31011702
Haemophilia. 2005 Nov;11(6):598-602
pubmed: 16236109
Haemophilia. 2004 Sep;10(5):565-71
pubmed: 15357785
J Outcome Meas. 1999;3(2):103-22
pubmed: 10204322
Pediatr Phys Ther. 2006 Winter;18(4):237
pubmed: 17108795
Haematologica. 2019 Sep;104(9):1702-1709
pubmed: 31399527
Arch Phys Med Rehabil. 1989 Nov;70(12):857-60
pubmed: 2818162
Haemophilia. 2018 Mar;24(2):e33-e49
pubmed: 29178149
Arthritis Care Res. 1991 Dec;4(4):143-9
pubmed: 11188601
Neuromuscul Disord. 2007 Jun;17(6):459-69
pubmed: 17433675
Eur J Haematol. 2018 Apr;100 Suppl 1:25-33
pubmed: 29498782

Auteurs

Sébastien Lobet (S)

Haemostasis and Thrombosis Unit, Division of Hematology, Clinique Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Secteur de Kinésithérapie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Neuromusculoskeletal Lab (NMSK), Secteur des Sciences de la Santé, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Catherine Lambert (C)

Haemostasis and Thrombosis Unit, Division of Hematology, Clinique Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Anthe Foubert (A)

Research Group MOVANT, Department of Rehabilitation Sciences and Physiotherapy (REVAKI), University of Antwerp, Wilrijk, Belgium.
Pain in Motion, International Research Group.
Faculté des Sciences de la Motricité, Université Catholique de Louvain (UCLouvain), Louvain-la-Neuve, Belgium.

Valérie-Anne Chantrain (VA)

Research Group MOVANT, Department of Rehabilitation Sciences and Physiotherapy (REVAKI), University of Antwerp, Wilrijk, Belgium.
Pain in Motion, International Research Group.
Faculté des Sciences de la Motricité, Université Catholique de Louvain (UCLouvain), Louvain-la-Neuve, Belgium.

Nathalie Roussel (N)

Research Group MOVANT, Department of Rehabilitation Sciences and Physiotherapy (REVAKI), University of Antwerp, Wilrijk, Belgium.

Mira Meeus (M)

Research Group MOVANT, Department of Rehabilitation Sciences and Physiotherapy (REVAKI), University of Antwerp, Wilrijk, Belgium.
Pain in Motion, International Research Group.
Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.

Ann Devos (A)

Hemostasis and Thrombosis Unit, Division of Pediatric Hematology, University Hospital Antwerp, Antwerp, Belgium.

Philip Maes (P)

Hemostasis and Thrombosis Unit, Division of Pediatric Hematology, University Hospital Antwerp, Antwerp, Belgium.

Cedric Hermans (C)

Haemostasis and Thrombosis Unit, Division of Hematology, Clinique Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Massimo Penta (M)

Institute of Neuroscience, Université catholique de Louvain, Louvain-la-Neuve, Belgium.
Arsalis SRL, Glabais, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH